Cargando…

Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients

For high-risk breast cancer patients with positive axillary lymph nodes, dose-dense every-two-week epirubicin/cyclophosphamide-paclitaxel (ddEC-P) regimen is the optimal postoperative adjuvant therapy. However, this regimen is limited by the grade 3/4 neutropenia and febrile neutropenia (FN). There...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fan, LingHu, RuiXia, Zhan, XingYang, Li, Ruisheng, Feng, Fan, Gao, Xudong, Zhao, Lei, Yang, Junlan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668117/ https://www.ncbi.nlm.nih.gov/pubmed/29108384 http://dx.doi.org/10.18632/oncotarget.18145

Ejemplares similares

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
por: Ashrafi, Farzaneh, et al.
Publicado: (2018)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen
por: Alshamrani, Majed A., et al.
Publicado: (2019)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity
por: Kumari, Monika, et al.
Publicado: (2020)

Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children
por: Thakkar, Dhwanee, et al.
Publicado: (2021)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial
por: Mei, Qi, et al.
Publicado: (2022)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Effects of different doses of granulocyte colony-stimulating factor mobilization therapy on ischemic cardiomyopathy
por: Huang, Rongchong, et al.
Publicado: (2018)

Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
por: Baik, Seong Wan, et al.
Publicado: (2003)

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study
por: Liu, Chang, et al.
Publicado: (2021)

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
por: Cox, J E, et al.
Publicado: (2014)

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
por: Kanfer, E. J., et al.
Publicado: (1998)

Proper nomenclature for the human granulocytic ehrlichiosis agent.
por: Bakken, J S, et al.
Publicado: (2001)

Pegylated recombinant human granulocyte colony‐stimulating factor regulates the immune status of patients with small cell lung cancer
por: Sun, Jing, et al.
Publicado: (2020)

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer
por: Ji, Xiang, et al.
Publicado: (2021)

Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor
por: Zhao, Tong, et al.
Publicado: (2023)

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial
por: Wang, Cunliang, et al.
Publicado: (2022)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study
por: Wadhwa, Meenu, et al.
Publicado: (2015)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen
por: Rigacci, Luigi, et al.
Publicado: (2014)

Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia
por: WU, FENG-PENG, et al.
Publicado: (2015)

Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model
por: Chen, Jinqiu, et al.
Publicado: (2018)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis
por: Zhang, Fen, et al.
Publicado: (2020)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival
por: Fan, Zhisong, et al.
Publicado: (2018)

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies
por: Wen, Jingjing, et al.
Publicado: (2023)

Metrics, Dose, and Dose Concept: The Need for a Proper Dose Concept in the Risk Assessment of Nanoparticles
por: Simkó, Myrtill, et al.
Publicado: (2014)

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
por: Steward, W. P., et al.
Publicado: (1990)

Inflammation-mediated fetal injury by maternal granulocyte-colony stimulating factor and high-dose intraamniotic endotoxin in the caprine model
por: Sezik, Mekin, et al.
Publicado: (2019)

Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic
por: Wei, Chong, et al.
Publicado: (2021)

A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes
por: Zhu, Huan, et al.
Publicado: (2021)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013: A Retrospective Study
por: Si, Wen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k0c5gct05s5us31his2k3aoh8l